Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
- Conditions
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1790
- Registration Number
- NCT02139046
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 189
- Registration Number
- NCT02128490
- Locations
- 🇺🇸
Benny Green MD PA Family Practice, Little Rock, Arkansas, United States
🇺🇸Long Beach Center for Clinical Research, Long Beach, California, United States
🇺🇸Central Kentucy Reseach Associates, Lexington, Kentucky, United States
Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3366
- Registration Number
- NCT02099682
Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3502
- Registration Number
- NCT02099708
Effect of Proton Pump Inhibitors on Endothelial Function
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 21
- Registration Number
- NCT02022280
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14965
- Registration Number
- NCT01990339
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
- Conditions
- Interventions
- First Posted Date
- 2013-09-20
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01946971
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Lansoprazole in Preterm Infants With Reflux
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01778101
- Locations
- 🇰🇷
Seoul National University Children's Hospital, Seoul, Korea, Republic of
A Study of LY2940680 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01681186
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 161
- Registration Number
- NCT01667718
- Locations
- 🇨🇳
Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.